Monday, Oct. 1: Policy Uses of Cost-Effectiveness Analysis – HIV prevention and control . by Donald S. Shepard, Ph.D. Schneider Institute for Health Policy Heller School, MS 035 Brandeis University Waltham, MA 02454-9110 USA Tel: 781-736-3975 • Fax: 781-736-3965
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Donald S. Shepard, Ph.D.
Schneider Institute for Health Policy
Heller School, MS 035
Waltham, MA 02454-9110 USA
Tel: 781-736-3975 • Fax: 781-736-3965
E-mail: [email protected]
Background: Coverage of sildenafil by health
insurance plans is a contentious issue.
Objective: To evaluate the cost-effectiveness of sildenafil treatment for erectile dysfunction.
Design: A Markov decision model to estimate the incremental cost-effectiveness of sildenafil compared with no drug therapy.
Data Sources: Values for the efficacy and safety of sildenafil and quality-of-life utilities were obtained from the published medical literature. Base-case values were chosen to bias against sildenafil use.
Target Population: Men 60 years of age with erectile dysfunction.
Time Horizon: Lifetime.
Perspective: Societal and third-party payer.
Intervention: Sildenafil or no treatment in identical hypothetical cohorts.
Outcome Measures: Cost per quality-adjusted life-year (QALY) gained.
Results of Base-Case Analysis:
The cost per QALY gained for sildenafil treatment compared with no therapy was $11 290 from the societal perspective and $11 230 from the third-party payer perspective.
Results of Sensitivity Analysis:
From the societal perspective, the cost per QALY gained associated with sildenafil was less than $50 000 if treatment-related morbidity was less than 0.8% per year, mortality was less than 0.55% per year, treatment was successful in more than 40.2% of patients, or sildenafil cost less than $244 per month. The results were sensitive to variation of erectile dysfunction utilities, but cost per QALY gained was less than $50 000 if successful treatment increased utility values by 0.05 or more on a scale of 0 (death) to 1 (perfect health).
In an analysis biased against use of sildenafil, the cost-effectiveness of sildenafil treatment compared favorably with that of accepted therapies for other medical conditions.
This lecture addresses how cost-effectiveness analysis could contribute to a current policy question facing developing countries: the screening and treatment of pregnant women for HIV to reduce mother-to-child transmission, and other issues around controlling HIV.
* Inciardi JA, Surratt HL, Telles PR. Sex, Drugs and HIV/AIDS in Brazil. Boulder Co: Westview, 2000. Chapter 4, HIV-AIDS prevention-intervention in Rio de Janeiro, 61-74.
* Freedberg KA et al. “Cost-effectiveness of combination antiretroviral therapy for HIV disease.” N Engl J Med 2001; 334(11):824-31.
The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease.
Freedberg, Kenneth A. at al.
Background: Combination antiretroviral therapy with a combination of three or more drugs has become the standard of care for patients with human immunodeficiency virus (HIV) infection in the United States. We estimated the clinical benefits and cost effectiveness of three-drug antiretroviral regimens.
We developed a mathematical simulation model of HIV disease, using the CD4 cell count and HIV RNA level as predictors of the progression of disease. Outcome measures included life expectancy, life expectancy adjusted for the quality of life, lifetime direct medical costs, and cost effectiveness in dollars per quality-adjusted year of life gained. Clinical data were derived from major clinical trials, including the AIDS Clinical Trials Group 320 Study. Data on costs were based on the national AIDS Cost and Services Utilization Survey, with drug costs obtained from the Red Book.
For patients similar to those in the AIDS Clinical Trials Group 320 Study (mean CD4 cell count, 87 per cubic millimeter), life expectancy adjusted for the quality of life increased from 1.53 to 2.91 years, and per-person lifetime costs increased from $45,460 to $77,300 with three-drug therapy as compared with no therapy. The incremental cost per quality-adjusted year of life gained, as compared with no therapy, was $23,000.
Results (continued): On the basis of additional data from other major studies, the cost-effectiveness ratio for three-drug therapy ranged from $13,000 to $23,000 per quality-adjusted year of life gained. The initial CD4 cell count and drug costs were the most important determinants of costs, clinical benefits, and cost effectiveness.
Treatment of HIV infection with a combination of three antiretroviral drugs is a cost-effective use of resources.
* Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of Human Immunodeficiency Virus type 1. N Engl Med 2000; 343:982-91.
Purpose: See how cost-effectiveness analysis can be applied to a subject of interest to you.
Background: Select and cite an article or report of interest to you that describes the effectiveness or cost-effectiveness of a clinical intervention or program in a human services sector. For suggestions or help in identifying articles, see the instructor or teaching assistant. For example, the instructor’s report, “Economic analysis of anti-viral therapy in Botswana” provides data on the cost-effectiveness of AZT for pregnant women. A copy is available on the web site under “downloads.” Two types of papers are possible.
Alternative A: Perform a preliminary cost-effectiveness analysis. If the study is an effectiveness study only, perform a preliminary cost-effectiveness analysis. Clearly indicate the alternatives you wish to compare and the effectiveness measure, and provide illustrative results. Use existing data where readily available, and explicitly assume values for other the unknown data. Interpret the findings. Discuss what kinds of data would be needed to convert the preliminary study into a more valid cost-effectiveness study, and where would they be obtained? Which items do you think are most critical?
Alternative B: Discuss a cost-effectiveness analysis. If the study is a cost-effectivenessstudy, discuss the appropriateness of the data, analysis, and interpretation, and put the results in a larger context. For example, compare the intervention under study with other interventions for the same disease or the same population.
Submission: The length of the paper should be about 6 double spaced pages, including any tables or figures per student. Two or more students may work together and submit a joint paper that is proportionally more extensive, and longer if desired (6 pages per student). Please submit to Linda Purrini, administrative assistant, Heller G6, tel: 781-736-3930, [email protected] Also, please include a copy a summary, abstract, or full copy of the article with your submission. The paper may also be submitted electronically to Ms. Purrini.
Schedule: Due Thursday, Oct. 25, 2001 (10 days after the last class).
Evaluation: The module will be graded according to each student’s registration (audit, pass-fail, or letter grade) based on this final exercise, other exercises, and class participation. In addition, the instructors plan to give written comments on this exercise. The instructors look forward to your papers.
Monday, Oct. 8, 6 pm – 9 pm
Monday, Oct. 15, 6 pm – 9 pm